A switchable CAR-T cell platform comprises a universal receptor expressed on T cells and tumor-targeting adapter molecules. Here the authors propose an APRIL- and BAFF-based switchable CAR strategy for ligand-mediated CAR-T-cell activation, showing anti-tumor activity in models of B-cell malignancies.
- Shuhong Li
- Licai Shi
- Yu J. Cao
